Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Columbia University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
University of Florida
Cellectar Biosciences, Inc.
Nuvation Bio Inc.
Cancer Research UK
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
Turning Point Therapeutics, Inc.
Dana-Farber Cancer Institute
Virginia Commonwealth University
Second Affiliated Hospital, School of Medicine, Zhejiang University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
University of California, San Francisco
Tufts Medical Center
University of California, San Francisco
St. Jude Children's Research Hospital
Deciphera Pharmaceuticals, LLC
Assistance Publique - Hôpitaux de Paris
Bristol-Myers Squibb
Northwell Health
University College, London
Virginia Commonwealth University
AbbVie
Northwestern University
University of Pittsburgh
Shenzhen BinDeBio Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Case Comprehensive Cancer Center
Duke University
Jonsson Comprehensive Cancer Center
Duke University
Children's Oncology Group
INSYS Therapeutics Inc